Ongoing Pelareorep Clinical Studies
Programs | Combination | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Milestone |
---|---|---|---|---|---|---|---|
Breast Cancer |
|||||||
BRACELET-1
|
![]() |
HR+/HER2-mBC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
ORR, PFS, evolving OS H1 '23
|
AWARE-1
|
![]() |
HR+/HER2-BC |
Window of Opportunity Study
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Final Data Q4 '22 |
IRENE
|
Retifanlimab* | (TNBC) |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Phase 2 Safety Data Q4 '21 |
Gastro-Intestinal Cancer |
|||||||
GOBLET
|
![]() |
1L Adv/Metastatic Pancreatic Cancer |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Interim Data Q4 '22 |
GOBLET
|
![]() |
1L# mCRC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
- |
GOBLET
|
![]() |
3L mCRC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Safety run-in Complete |
GOBLET
|
![]() |
2L Unresectable Anal Cancer |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
- |
*Anti-PD-1 checkpoint inhibitor in development by Incyte (also known as INCMGA00012); mBC: Metastatic Breast Cancer; BC: Breast Cancer; ORR: Overall Response Rate; PFS: Progression-Free Survival, OS: Overall Survival; TNBC: Triple-Negative Breast Cancer; Adv: Advanced; L: Line; 1L#: First-line MSI-high focused; mCRC: Metastatic Colorectal Cancer